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Abstract
Opioid use disorder (OUD) is a major public health burden. Opioids long have been
shown to disrupt sleep and sleep disruption enhances the likelihood of addiction relapse in
humans. The National Institutes of Health (NIH) refers to the mouse as one of the most powerful
animal systems to study because of the genetic homologies between human and mouse. Prior to
the present research, no studies have quantified the effect of opioids on states of sleep and
wakefulness in mice. The current study was designed to test the hypothesis that acute
administration of buprenorphine, morphine, or fentanyl disrupts sleep/wake architecture in
C57BL/6J (B6) mice. Adult male mice (n = 8) were housed in a temperature-controlled
environment and a 12:12 h light:dark cycle with ad libitum access to food and water. Mice were
anesthetized with isoflurane for implantation of a telemeter (DSI HD-X02) and electrodes for
wireless recording of cortical electroencephalogram (EEG) and dorsal neck muscle
electromyogram (EMG). These signals were used to objectively quantify wakefulness, NREM
sleep, and REM sleep in 10-s bins. Every mouse received at least one intraperitoneal injection
(0.3 mL) each of saline (control) and an antinociceptive dose of buprenorphine, morphine, and
fentanyl separated by one week. Each recording was scored independently by two individuals,
one of whom was blinded to the treatment condition. Sleep scoring concordance scores were
greater than 90%. These results, expressed as percent change from saline, summarize 64
recordings. Buprenorphine significantly increased wakefulness (151% ;p=0.0078) and eliminated
both NREM and REM sleep. Morphine significantly increased wakefulness (142% ;p=0.0078),
decreased NREM sleep (-94% ;p=0.0078) and eliminated REM sleep. Fentanyl significantly
increased wakefulness (105% ;p=0.0078), decreased NREM sleep (-68% ;p=0.0078) and
decreased REM sleep (-89% ;p=0.0078).
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Chapter 1: Introduction
Opioids are effective for managing pain, but clinical1-7 and preclinical8-11 studies show
that acutely administered opioids cause sleep disruption. Chronic opioid use has been linked to a
number of negative effects such as disrupted sleep architecture,6 daytime fatigue,5 and
hypersomnolence.1 Opioid use disorder (OUD) is a major burden on public health.12 Medical
assisted therapy for OUD includes the opioids methadone, naltrexone, and buprenorphine.12
Characterizing the sleep disruption caused by opioids is an important step towards developing
treatments for pain with reduced unwanted side effects.
Similar to breathing, sleep is a biological rhythm that is organized temporally13 and
comprised of specific neurochemical and electrophysiological changes within the brain.14
Multiple brain regions including the brain stem, hypothalamus, and basal forebrain converge to
actively produce behavioral states of wakefulness, non-rapid eye movement (NREM) sleep, and
rapid eye movement (REM) sleep.15,16 Cortical electroencephalographic (EEG) activity
associated with NREM sleep is typically within the 0.5 to 4 Hz range (i.e., delta waves) and in
REM sleep it is in the 4 to 8 Hz range (i.e., theta waves).17 Monoamines within the brain have
long been known to promote wakefulness and cortical acetylcholine plays a major role in
generating the active brain-states of wakefulness and REM sleep (otherwise known as
paradoxical sleep because the EEG is similar to the EEG of wakefulness).13,18 Adenosine
increases in metabolically active brain regions during periods of prolonged wakefulness and
suppresses wake-promoting neurotransmitters, thereby contributing to the generation of NREM
and REM sleep.13,18
The brain’s electrical18 and neurochemical19 activity markedly differs between states of
sleep and wakefulness.13 The physiological and temporal organization that produces healthy,
1

restful sleep is described as sleep architecture and provides functional metrics (i.e., latency to
sleep onset, number of bouts of NREM sleep and REM sleep, and fragmentation of these
episodes) for measuring sleep quality and diagnosing sleep disorders.13,14 Sleep architecture in
adult humans can be significantly altered even after a single dose of oral opioids.2,20 Patients with
chronic pain who are prescribed opioids report more sleep impairment than patients who are not
prescribed opioid medications.3 Due to the addictive and deleterious side effects of opioids, it is
not ethically possible to perform mechanistic studies in humans. To overcome these limitations,
non-human animals are used to fill these gaps in knowledge.
Opioids increase wakefulness and inhibit the NREM and REM phases of sleep in rats.9 In
cat, microinjection of morphine into the nucleus of the solitary tract disrupts sleep architecture.11
Studies of rat show that morphine administered to the basal forebrain or given systemically
decreases cortical acetylcholine release and slows EEG activity.10 Buprenorphine has been
shown to disrupt sleep and decrease concentrations of adenosine in sleep-regulating brain regions
in rats.8 The C57BL/6J (B6) mouse carries special relevance, as the National Institutes of Health
(NIH) refers to the mouse as the premier mammalian model system for biomedical research.21
B6 mice are genetically tractable in vivo models that facilitate mechanistic investigation into a
plethora of human illnesses.22 There is more than 90% homology between the mouse and human
genome23 supporting the view that studies of mice can help understand normal and abnormal
physiology and behavior in humans. Taken together, the foregoing feasibility and translational
potential described here supports the view that studies of mice offer a powerful model for
investigating the neurochemical and electrophysiological characteristics regulating human sleep
and wakefulness.24
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Buprenorphine is an opioid that acts as a partial mu-opioid receptor agonist and full
kappa-opioid receptor antagonist.25 Buprenorphine has a longer half-life than fentanyl or
morphine.26 By contrast, morphine and fentanyl are full mu-opioid receptor agonists. This
pharmacological difference allows buprenorphine to be a feasible and common option for
substitution therapy in OUD.25 However, sleep quality is severely impaired by stable
buprenorphine or methadone treatment.3,27 Buprenorphine also causes sleep disruption that is
associated with increased depressive symptoms in clinical patients.27
Sleep disturbance significantly predicts the outcome of treatment for illicit drug and
alcohol use disorder in primary care,28 and many opioids cause sleep disruption that enhances the
likelihood of relapse.29 Sleep disruption can also delay wound healing30 and increase levels of
inflammatory markers such as interleukin 6.31 Poor sleep quality has been indicated to exacerbate
negative emotional states, which can lead to addiction relapse.32 Sleep disruption can also cause
hyperalgesia (increased perception of pain), which leads to higher doses of opioids required to
achieve the effect of antinociception.13,33 Taken together, these studies highlight the importance
of characterizing opioid-induced sleep disruption.
A systematic review of the literature revealed no similar studies aiming to elucidate
whether opioids alter states of sleep and wakefulness in the B6 mouse. This study aimed to fill
this gap in knowledge by testing the hypothesis that systemic opioid administration disrupts
sleep/wake states in B6 mice.

3

Chapter 2: Materials and Methods
Animals
All procedures in this study were reviewed and approved by the University of Tennessee
Institutional Animal Care and Use Committee and were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of Laboratory Animals.34 Subjects
included mature, male C57BL/6J (B6) mice (Stock# 000664; n = 8) purchased from the Jackson
Laboratory. Mice were housed with littermates on arrival, and cages and litter were changed
weekly. Mice were given one week to adapt to the laboratory and conditioned to being handled
for an additional week before beginning experiments. They were housed in a temperaturecontrolled environment and maintained in a 12:12 h light:dark cycle. Food and water were
provided ad libitum. Teklad 8640 rodent chow was purchased from Research Diets, Inc., (New
Brunswick, NJ, USA). At the time of the study, mice averaged 27.4 ± 1.14 (mean ± SD) weeks
of age.

Telemeter implantation
The mice were anesthetized with isoflurane in order to subcutaneously implant a
telemeter (HD-X02, Data Sciences International (DSI), Minneapolis, MI.) that made it possible
to record electroencephalogram (EEG) and electromyogram (EMG) (Fig. 1). The telemeters
were connected to bipolar electrodes implanted in the dorsal neck muscles for recording EMG.
An additional pair of electrodes was implanted via craniotomies above the prefrontal cortex
(A=31; L=4; V=-2) using stereotaxic coordinates of a mouse brain atlas.35 These bipolar cortical
electrodes were used to record the EEG. Mice also were implanted subcutaneously with a radiofrequency identification (RFID) chip (ID-100B 1.4, Trovan, Ltd., United Kingdom) that gave
each mouse a unique identification number. During surgery, core body temperature was
4

monitored and maintained at 37 degrees C, and respiratory rate was recorded every 5 min. At
completion of implantation, the incision was closed, and mice were placed in a warm recovery
chamber where they were monitored continually until they were ambulatory. All mice recovered
without difficulty and within 24 h exhibited normal feeding and grooming behaviors. After
telemeter implantation the mice were housed individually throughout the remainder of the study.
The telemeters (Fig. 1), when chronically implanted wirelessly transmit recordings of
EEG and EMG signals via antenna within the receiver pads beneath each mouse cage (Fig. 2).
The receiver pads are connected to the DSI Matrix 2.0 (MX2) instrumentation (not pictured) via
cables. This device facilitates communication between the implanted telemeter and the data
acquisition computer, which was utilized to filter and analyze the transmitted signals. Once
digitized, the EEG and EMG recordings were scored every 10 s for the duration of the recording
as wakefulness, NREM sleep, or REM sleep.

Figure 1. Illustration of a HD-X02 telemeter implanted subcutaneously in a mouse. The
drawing schematizes that electrodes placed above the cerebral cortex and in the dorsal neck
muscles were connected to the telemeter
(https://www.datasci.com/solutions/neuroscience?wvideo=7d1ni1696w). Manufacturer details
are from Data Sciences International (DSI). Source: https://www.datasci.com/docs/defaultsource/implantable-telemetry/hd-x02_s02.pdf?sfvrsn=4
5

Figure 2. Illustration of the experimental set up for a wireless recording of sleep and
wakefulness from freely moving B6 mice. Each mouse’s home cage was placed on a receiver
(black pad) numbered 1 to 4, which relayed the signal from the implanted telemeter to a
computer in another room (not shown) where they were analyzed. This permitted the
experimenter to monitor the recordings without disturbing the mice.

Recording States of Sleep and Wakefulness
After a week of surgical recovery, the signal-to-noise quality of the EEG and EMG
recordings were evaluated to ensure that they could be used to objectively score states of sleep
and wakefulness while mice were behaving freely in their home cage. Profiles of delta and theta
power, along with EMG amplitude, made it possible to accurately score the behavioral states of
sleep and wakefulness in each recording. States of wakefulness were characterized by low
amplitude EEG, the presence of maximal EMG signal (Fig. 3A), and a delta/theta ratio of 1:4.14
EEG frequencies from 0.5 to 4 Hz (delta waves) are typically seen during NREM sleep (Fig.
3B). EEG frequencies from 5 to 8 Hz (theta waves) are associated with REM sleep (Fig. 3C).
These recordings created an objective index of behavioral states during each experiment.
6

Figure 3. Illustration of EEG and EMG signals and characteristics of the behavioral states of (A)
wakefulness, (B) NREM sleep, and (C) REM sleep. All signals were taken from the same mouse
during a single recording session following injection of saline. The EEG signals are represented
in blue, and the EMG signals are shown in black. The abscissa shows three sequential 10-s
epochs, and the ordinate shows the amplitude of the signals (µV). Wakefulness was
characterized by low amplitude/high frequency EEG combined with high amplitude EMG.
NREM sleep has high amplitude/low frequency EEG (i.e., slow waves) with lower amplitude
EMG, and REM sleep has low amplitude/high frequency EEG (similar to waking) and very low
muscle activity shown by the EMG. Considered together, the instrumentation and recordings
illustrated by Figures 1 and 2 were used to record and objectively score states of sleep and
wakefulness for 4 h or 24 h after mice were injected with saline (control) or an opioid.

7

Experimental Design
Each mouse’s body weight was recorded prior to each experiment. Mean ± SD body
weight for mice used for this study was 34.8 ± 1.97 g. Data collection started immediately after
the mice received intraperitoneal (IP) injections (0.3 mL) of sterile saline (control) or saline
containing antinociceptive doses of buprenorphine36 (0.3 mg/kg), morphine37 (10 mg/kg), or
fentanyl38 (0.4 mg/kg). Recordings were performed for 4 h and began immediately postinjection. Experiments using a subset of animals (n = 4) were conducted to quantify opioid
effects on sleep and wakefulness for 24 h post-injection. A within-subjects design was used such
that every mouse received at least one IP injection of saline and each opioid treatment condition,
which was counter-balanced regarding the order of drug administration. Mice were given one
week for a washout period between injections. Data from repeated injections of the same drug
into the same mouse were averaged in order not to inflate degrees of freedom. After each
injection mice were returned to their home cages, which were placed on the telemeter receiving
pad. Use of the DSI telemeter system made it possible to obtain recordings of sleep and
wakefulness from mice freely ambulating in their home environment. Time of day for all
recordings was standardized to begin 1.5 h after lights on.

Signal Processing
The EEG and EMG recordings were analyzed using the DSI Neuroscore program. The
Ponemah software was set to record signals at a sampling rate of 500 Hz. EEG signals were
filtered between 0.5 and 30 Hz, and EMG signals between 10 and 100 Hz. Each 4-h and 24-h
recording was analyzed in 10-s epochs (i.e., 4-h recording = 1,440 epochs), which were scored
for sleep and wakefulness. Epochs that contained behavioral state transitions (i.e., transitions
from wakefulness to NREM sleep, NREM sleep to REM sleep, etc.) were scored based on the
8

behavioral state that occurred for more than half of the epoch. The Neuroscore software created a
fast Fourier transformation (FFT) of the EEG signal which quantified the delta and theta EEG
power for each 10-s epoch of the recording. All recordings were double-scored, and the duplicate
evaluators were blinded to the treatment conditions. Recordings that did not achieve a >90%
concordance between evaluators were rescored until this criterion was reached. Microsoft Excel
was used to plot states of wakefulness, NREM sleep, and REM sleep as a function of time across
the 4-h recording for each injection condition (Fig. 4).

Statistics Analyses
Dependent variables of this study included percent of time spent in each behavioral state,
number of episodes for each state, duration of the state episodes, and latency to onset of NREM
and REM sleep. These measures were quantified as the median ± interquartile range (IQR). Each
of these variables represents a key component of sleep architecture and thus offered insight into
which aspects of sleep were altered by the administered opioids. Descriptive and inferential
statistical analyses were performed using Prism 8.3.0 (GraphPad Software, San Diego, CA). The
Wilcoxon signed rank (non-parametric) test, Analysis of variance (ANOVA), and Tukey’s
multiple comparison test were used for post-hoc analysis. Statistical significance was shown by
asterisks and defined by a probability value of (*p<0.05 or **p<0.0001).

9

Chapter 3: Results
3.1 Opioids altered the timing of sleep and wakefulness in B6 mice
Systemically administered opioids disrupted the sleep/wake architecture of B6 mice as
illustrated by Figure 4. The temporal organization of sleep was altered for all recordings
following opioid injection that were analyzed in this study. These representative plots illustrate
that systemically administered opioids disrupted sleep architecture relative to saline (control).
The number of transitions and episodes for each state was decreased, as shown by fewer black
bars for opioid conditions when compared to saline. The duration of sleep episodes was
decreased and waking episodes were increased, which is indicated by the change in the width of
the black bars. The latency to onset of sleep was delayed. This is illustrated by the first sleep
episodes moving further away from time point zero following administration of fentanyl, or
morphine, and by the elimination of sleep caused by buprenorphine administration.

Figure 4. This figure shows the temporal organization of wakefulness (WAKE), non-rapid eye
movement (NREM) sleep, and rapid eye movement (REM) sleep plotted as a function of time
after systemic drug delivery. Each row represents the 4-h time course of sleep and wakefulness
for one mouse. Each column shows injection conditions of saline (control), morphine, fentanyl,
10

and buprenorphine. The abscissa of each graph represents the time in hours (h) following
intraperitoneal injection at time point zero. The ordinate indicates the behavioral states of
wakefulness, NREM sleep, and REM sleep. The histogram height provides information about
whether the mouse was awake or asleep, and the width of each histogram indicates the duration
of time spent in each state.

3.2 Opioids altered the percent of 4-h recoding time in states of sleep and wakefulness
The percent of time spent in each measured behavioral state as a function of the drug
condition is summarized for 4-h recordings in Figure 5.

3.3 Opioids caused disruption of sleep and wakefulness lasting up to 16 hours
A subset of animals (n = 4) was used to quantify percent of time spent in states of
wakefulness, NREM sleep, and REM sleep for 24 h post-injection. These studies aimed to
determine the duration of the opioid effects on sleep and wakefulness. Sleep/wake cycles in
mammals are closely tied to cycles of light and dark (i.e., humans are diurnal and mice are
nocturnal), so it was important to quantify the recordings during periods of light (7:00 a.m. to
7:00 p.m.) and dark (7:00 p.m. to 7:00 a.m.). The change in the percent of time spent in each
measured behavioral state as a function of the drug condition is summarized for 24-h postinjection in Figure 6.

3.4 Opioids disrupted the temporal organization of 24-h sleep/wake architecture
The time course (in 2-h intervals) for percent of time spent in each measured behavioral
state as a function of the drug condition is summarized for 24-h post-injection in Figure 7.
11

Figure 5. This figure illustrates the group data for percent of time spent in behavioral states of
sleep and wakefulness as a function of the treatment condition. The data points above each
histogram represent data from individual mice (n = 8). Histogram height conveys the median.
Black lines between the data points illustrate the interquartile range (IQR). (A) One-way
ANOVA showed that mice spent significantly more time in wakefulness after injection of each
opioid when compared to saline (F=118.2; df=3,28; p<0.0001). (B) indicates NREM sleep was
significantly decreased by morphine and fentanyl and was eliminated by buprenorphine
(F=106.5; df=3,28; p<0.0001). (C) illustrates that mice spent significantly less time in REM
sleep, which was eliminated by both morphine and buprenorphine (F=155.4; df=3,28; p<0.0001).
Across 4 h, opioids caused an increase in wakefulness and a decrease in NREM and REM sleep
compared with saline. Tukey’s multiple comparison test revealed significant (**p<0.0001)
differences for all three opioid treatment conditions relative to saline during a 4-h recording.
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Figure 6. This figure illustrates that opioids significantly altered the percent of time spent in
each behavioral state during the light phase, the dark phase, and across the 24-h period. Two-way
ANOVA revealed significant main effects and an interaction due to injection condition and
light/dark phases for percent of 24-h recording spent in behavioral states. On the ordinate of
every graph is the percent of time spent in each behavioral state plotted as a function of injection
condition. Histogram height represents the median and the black lines convey the IQR. The
abscissa of each graph shows the 24-h period and both the light (7:00 a.m. to 7:00 p.m.) and dark
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(gray shading indicating 7:00 p.m. to 7:00 a.m.) periods. (A) Two-way ANOVA revealed mice
spent significantly more time in wakefulness following opioid injection relative to saline
(F=42.17; df=3,24; p<0.0001); light vs dark comparison revealed a significant main effect
(F=5.745; df=1,24; p=0.0247), and evaluation of the interaction indicated significant differences
as a function of drug and light/dark phase (F=26.83; df=3,24; p<0.0001). (B) indicates that
NREM sleep was significantly decreased by opioids compared to saline (F=40.02; df=3,24;
p<0.0001). There was a significant effect of light/dark phase (F=6.533; df=1,24; p=0.0173) and a
significant interaction between injection condition and light/dark phase (F=19.37; df=3,24;
p<0.0001). (C) illustrates that mice exhibited significantly less REM sleep following opioid
injection when compared with saline during the 24-h period and the light/dark cycles (F=9.482;
df=3,24; p=0.0003). Light vs dark comparisons revealed no differences, and evaluation of the
interaction between injection condition and light/dark phases indicated significant differences
(F=45.04; df=3,24; p<0.0001). Across 24 h, opioids caused an increase in wakefulness and a
decrease in NREM and REM sleep compared with saline. Tukey’s multiple comparison test
revealed significant (*p<0.05 and **p<0.0001) differences for percent state following morphine
and buprenorphine relative to saline for the 24-h period, though there were no differences
following acute fentanyl administration. There were significant (**p<0.0001) differences for
percent of time in behavioral states following all three opioid treatment conditions compared
with saline during the light cycle. Percent of time spent in each behavioral state following
fentanyl or buprenorphine administration was significantly (*p<0.05) different from saline
during the dark cycle, however there were no morphine effects on sleep and wakefulness during
the dark cycle.
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Figure 7. Illustration of the time course for percent sleep and wakefulness for (n = 4) mice
during 24-h recordings. This aids in characterizing behavioral states as altered by each of the
four injection conditions. The differences in time course for percent state of wakefulness, NREM
sleep, and REM sleep across a 24-h recording are plotted in 2-h time intervals for each drug
condition. This figure illustrates 10.5 h of light, followed by 12 h of dark, and 1.5 h of light that
comprised the 24-h recording. The data points on the time-course plot represent the median and
the IQR. The shaded area from 10.5 h to 22.5 h post-injection indicates the dark period. Twoway ANOVA evaluated the potential for main effects on state due to drug, time post-injection,
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and for a drug by time interaction (A). Mice spent significantly more time in wakefulness after
opioid injection as a function of time (F=4.77; df=11,144; p<0.0001) and drug (F=28.21;
df=3,144; p<0.0001). There was also a significant drug by time interaction for the percent of
time in wakefulness (F=1.842; df=33,144; p=0.0077). (B) ANOVA revealed mice spent
significantly less time in NREM sleep as a function of time (F=7.495; df=11,144; p<0.0001) and
drug (F=27.92; df=3,144; p<0.0001). NREM sleep was significantly decreased as a function of
the interaction between injection condition and time (F=2.578; df=33,144; p<0.0001). (C)
illustrates that mice spent significantly less time in REM sleep following opioid injection as a
function of drug (F=1.897; df=3,144; p<0.0001). ANOVA revealed there was no time effect on
REM sleep, but the drug by time interaction was significant (F=3.556; df=33,144; p<0.0001).
Tukey’s multiple comparison test revealed significant (*p<0.05) differences in the time course of
behavioral states following acute opioid administration when compared with saline at each 2-h
time segment. Asterisks, color-coded utilizing the figure legend for fentanyl, morphine, and
buprenorphine, were placed above each 2-h time interval. This illustrated opioid treatment
conditions that caused a significant (*p<0.05) change in sleep and wakefulness, relative to saline,
at each 2-h period. For instance, the orange asterisks at 4-h post-injection for every measured
behavioral state shows that buprenorphine significantly (*p<0.05) increased wakefulness
(relative to saline in blue) and deceased both NREM and REM sleep during this 2-h interval.
NREM sleep following fentanyl or morphine was significantly (*p<0.05) different from saline
levels at 4 h and 6 h post-injection, respectively. After buprenorphine injection, REM sleep
required approximately 10 h to return to saline levels. Post-administration of fentanyl or
buprenorphine mice spent significantly (*p<0.05) more time in REM sleep (relative to saline) at
14 h and 16 h post-injection, respectively, during the dark cycle.

16

3.5 Opioids altered the amount of time spent in states of sleep and wakefulness during
periods of light and dark
The percent change for time mice spent in each measured behavioral state as a function
of the injection condition is summarized for the light and dark cycles in Figure 8.

3.6 Opioids decreased the number of episodes of wakefulness, NREM sleep, and REM sleep
The difference in the number of episodes for each measured behavioral state as a function
of the drug condition 4-h post-injection is summarized in Figure 9.

3.7 Opioids decreased the number of episodes of sleep and wakefulness during a 24-h
recording
Differences in the number of episodes for each measured behavioral state as a function of
the drug condition 24-h post-injection are summarized in Figure 10.

Figure 8. Illustration of the percent change (from saline) for each measured behavioral state
17

during the light and dark periods following opioid administration. The points above each
histogram represent data from each mouse (n = 4). On the ordinate of every graph is the percent
change relative to saline for amount of time spent in each behavioral state as a function of the
injection condition. The top of each histogram represents the median and the black lines convey
the IQR. The abscissa of each graph shows both the light (7:00 a.m. to 7:00 p.m.) and dark (7:00
p.m. to 7:00 a.m.) phases. (A) One-way ANOVA showed that mice spent significantly more time
in wakefulness as a function of drug (F=20.7; df=3,24; p<0.0001) and revealed a significant
main effect of light/dark cycle (F=66.21; df=1,24; p<0.0001). The drug by time interaction was
also significant regarding the time spent in wakefulness (F=16.78; df=3,24; p<0.0001). (B)
indicates that NREM sleep was significantly decreased by opioids compared to saline (F=28.91;
df=3,24; p<0.0001), and there was a significant main effect of light/dark period (F=16.41;
df=1,24; p=0.0005). There was also a significant drug by time interaction for the percent of time
in NREM sleep (F=6.634; df=3,24; p=0.002). (C) illustrates that mice spent significantly less
time in REM sleep following opioid injection when compared to saline (F=8.672; df=3,24;
p=0.0004). There was a significant main effect of light/dark cycle (F=77.67; df=1,24; p<0.0001)
and drug by time interaction (F=36.01; df=3,24; p<0.0001) regarding the time in REM sleep.
Tukey’s multiple comparison test revealed significant (*p<0.05 and **p<0.0001) differences for
all three opioid conditions compared to saline for the light cycle. Following morphine and
buprenorphine administration, NREM and REM were significantly (*p<0.05 and **p<0.0001)
different from saline during the dark cycle. Fentanyl had no effect on any of the three measured
behavioral states during the dark phase.
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Figure 9. This figure shows the decrease in the total number of waking, NREM, and REM sleep
episodes following opioid administration when compared to saline during the 4-h recordings for
(n = 8) mice . The total number of episodes for each behavioral state was decreased by opioids.
The ordinate of each graph illustrates the number of episodes as a function of drug condition.
Histogram height represents the median and the black lines convey the IQR. (A) shows that
opioids caused a significant decrease in the number of waking episodes relative to saline
(F=59.06; df=3,28; p<0.0001). (B) The number of NREM sleep episodes was significantly
decreased by morphine and fentanyl and was eliminated by buprenorphine (F=64.38; df=3,28;
p<0.0001). (C) The number of REM episodes was significantly decreased by all opioids
(F=109.8; df=3,28; p<0.0001). REM sleep episodes were eliminated by both morphine and
buprenorphine. Across 4 h, following opioid injection mice showed a decrease in the number of
waking, NREM sleep, and REM sleep episodes compared with saline. Tukey’s multiple
comparison test revealed significant (**p<0.0001) differences, relative to saline, in the number
of episodes for every measured behavioral state following fentanyl, morphine, or buprenorphine.
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Figure 10. This figure illustrates opioids significantly reduced the number of episodes for each
behavioral state during a 24-h period, and the light and dark phases. Two-way ANOVA revealed
significant main effects and an interaction due to injection condition and light/dark phases for the
number of episodes of wakefulness, NREM, and REM sleep during a 24-h recording. The data
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points above each histogram represent each mouse (n = 4). On the ordinate of every graph is the
number of episodes for each behavioral state as a function of injection condition. Histogram
height represents the median, and the IQR is shown by the black bars. The abscissa of each graph
shows the 24-h period and both the light (7:00 a.m. to 7:00 p.m.) and dark (7:00 p.m. to 7:00
a.m.) cycles, which is also represented by the shaded box. (A) shows mice exhibited significantly
fewer waking episodes after each opioid injection when compared to saline (F=33.15; df=3,24;
p<0.0001). There was a significant main effect of light/dark phase (F=14.91; df=1,24; p=0.0007)
and interaction between injection condition and light/dark phase for the number of waking
episodes (F=4.84; df=3,24; p=0.009). (B) indicates the number of NREM sleep episodes was
significantly decreased by opioids during a 24-h recording (F=33.75; df=3,24; p<0.0001). Light
vs dark comparisons revealed a significant main effect (F=15.52; df=1,24; p=0.0006), and
evaluation of the interaction was also significant regarding the number of NREM sleep episodes
(F=5.115; df=3,24; p=0.0071). (C) illustrates that mice had significantly fewer REM sleep
episodes after each opioid injection when compared to saline (F=11.55; df=3,24; p<0.0001).
ANOVA revealed a significant main effect of light/dark phase (F=5.38; df=1,24; p=0.0292), and
interaction between injection condition and light/dark phase for the number of REM sleep
episodes (F=31.15; df=3,24; p<0.0001). Across 24 h, following opioid injection mice showed a
decrease in the number of waking, NREM sleep, and REM sleep episodes when compared with
saline. Tukey’s multiple comparison test revealed significant (*p<0.05 and **p<0.0001)
differences for all three opioid treatment conditions compared with saline during the light cycle
and 24-h period. Behavioral states following administration of morphine or buprenorphine were
significantly (*p<0.05) different from saline during the dark cycle. There was no effect of
fentanyl on the number of episodes of sleep or wakefulness during the dark period.
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3.8 Opioids altered the duration of time mice spent in episodes of sleep and wakefulness
The change in the duration of the episodes for the measured behavioral states of
wakefulness, NREM, and REM sleep as a function of the drug condition is summarized for 4-h
recordings in Figure 11.

3.9 Opioids disrupted the duration of episodes of sleep and wakefulness during a 24-h
recording
Changes in the duration of the episodes for each behavioral state as a function of the drug
condition are shown for the 24-h period post-injection in Figure 12.

3.10 Opioids delayed the onset of NREM sleep and REM sleep
The change in the latency to onset of sleep as a function of the drug condition is
summarized for the 4-h period post-injection in Figure 13. 24-h recordings shown in Figure 14
made it possible to quantify the sleep latency that was eliminated by morphine (i.e., REM sleep)
and buprenorphine (i.e., NREM and REM sleep).
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Figure 11. This figure summarizes the difference in duration (in minutes) of states of
wakefulness, NREM, and REM sleep following saline or opioid administration. The duration of
Figure 1.HDthe
episodes for each behavioral state during a 4-h recording was disrupted by systemic opioids.
X02 telemeter
with DSI co.
specifications
The data points represent each mouse (n = 8). The ordinate of every graph illustrates the duration

Figure 11.
of the episodes (in minutes) as a function of drug represented as the median (histogram height)
and IQR (black lines). (A) shows that compared to saline, opioids caused significantly longer
waking episodes (F=41.35; df=3,28; p<0.0001). (B) indicates the duration of NREM sleep
episodes was significantly decreased by morphine and these episodes were eliminated by
buprenorphine (F=22.68; df=3,28; p<0.0001). (C) the duration of REM sleep episodes was
significantly decreased by fentanyl and eliminated by both morphine and buprenorphine
(F=28.98; df=3,28; p<0.0001). Across 4 h, following opioid injection mice showed an increase
in the duration of waking episodes and a decrease in the duration of NREM and REM sleep
episodes when compared with saline. Tukey’s multiple comparison test revealed significant
(*p<0.05 and **p<0.0001) differences for the duration of episodes of each behavioral state
between saline and all opioid treatment conditions. There was no effect of fentanyl on the
duration of waking and NREM sleep episodes during a 4-h recording.
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Figure 12. Illustration of the change in duration (in minutes) for each measured behavioral state
as a function of the drug condition during the light, dark, and 24-h phases. Two-way ANOVA
revealed potential main effects and an interaction due to injection condition and light/dark
phases on the duration of episodes during a 24-h period. The data points above each histogram
represent each mouse (n = 4). On the ordinate of every graph is the duration of episodes in
minutes for each behavioral state as a function of the injection condition. Histogram height
represents the median, and the IQR is shown by the black bars. The abscissa of each graph shows
the 24-h period and both the light (7:00 a.m. to 7:00 pm) and dark (7:00 pm to 7:00 a.m.) cycles,
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which is also represented by the shaded box. (A) shows that the trend across 24 h is for acute
opioid administration to increase the duration of waking episodes relative to saline. The median
(and IQR) for the duration of waking episodes following buprenorphine administration were
calculated (and illustrated above) excluding the outlier data point at 630 minutes during the light
cycle. Two-way ANOVA included data from every mouse and revealed no effect on the duration
of waking episodes as a function of drug, time, or the drug by time interaction during a 24-h
recording. (B) indicates the duration of NREM sleep episodes was significantly disrupted by
opioids (F=10.88; df=3,24; p=0.0001), and there was a significant main effect of light vs dark
cycle (F=20.95; df=1,24; p=0.0001). Evaluation of the interaction between injection condition
and light/dark phases was also significant for the duration of NREM episodes (F=3.959; df=3,24;
p=0.02). (C) illustrates the duration of REM sleep episodes was significantly disrupted by
opioids (F=4.177; df=3,24; p=0.0163). There was no effect of light/dark phase on the duration of
REM sleep episodes. The interaction between injection condition and light/dark phases was also
significant regarding the duration of REM episodes (F=13.13; df=3,24; p<0.0001). Across 24 h,
following opioid injection mice showed an increase in the duration of waking episodes and
decrease in the duration of NREM and REM sleep episodes when compared with saline. Tukey’s
multiple comparison test revealed significant (*p<0.05 and **p<0.0001) differences for all three
opioid treatment conditions relative to saline during the light cycle and 24-h period. However,
there was no effect on the duration of episodes for each behavioral state during the dark cycle
following injection of fentanyl, morphine, or buprenorphine when compared with saline.
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Figure 13. This figure shows the increase in latency to onset of NREM and REM sleep caused
by acute administration of saline, fentanyl, or morphine. Wilcoxon signed rank test revealed
opioids significantly increased the time from drug administration to the onset of sleep.
Recordings which did not contain NREM (i.e., n = 8 post-buprenorphine and n = 2 following
morphine) or REM sleep (i.e., n = 8 post-buprenorphine or morphine, and n = 4 following
fentanyl) were excluded from the Fig. 13 summary. On the ordinate of every graph is the latency
to onset of sleep (in minutes) as a function of drug represented as the median and IQR. (A)
Wilcoxon signed rank test showed the latency to onset of NREM sleep was significantly
increased following injection of fentanyl (Z=2.42; Mdn=141.1; p=0.0078) or morphine (Z=1.86;
Mdn=183.7; p=0.0313) relative to saline. NREM sleep was eliminated by buprenorphine and
during n = 2 morphine (4-h) recordings. (B) shows REM sleep was eliminated following
injection of fentanyl in n = 4 recordings. Wilcoxon signed rank test revealed there was no change
in the latency to onset of REM sleep in the remaining (n = 4) recordings of sleep and
wakefulness post-administration of fentanyl. Morphine and buprenorphine eliminated REM sleep
in 4-h recordings of sleep of wakefulness. Across 4 h, opioid administration caused an increase
in the latency to onset of NREM and REM sleep.
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Figure 14. Illustration of the increase in latency to onset of NREM and REM sleep as a function
of the drug condition for the 24-h recordings in (n = 4) mice. One-way ANOVA showed the
latency to onset of NREM and REM sleep was delayed by systemic opioids. On the ordinate of
every graph is the latency to onset of sleep (in minutes) as a function of drug. Histogram height
represents the median and the black bars show the IQR. (A) shows a significant increase in the
latency to NREM sleep onset following injection of opioids when compared with saline (F=22.3;
df=3,12; p<0.0001). (B) shows latency to onset of REM sleep was significantly increased by
fentanyl, morphine, or buprenorphine (F=28.78; df=3,12; p<0.0001). Across 24 h, following
opioid injection mice showed an increase in latency to onset of NREM and REM sleep relative to
saline. Tukey’s multiple comparison test revealed significant (*p<0.05 and **p<0.0001)
differences in the latency to onset of sleep following administration of fentanyl and
buprenorphine, respectively. Morphine had no effect on the onset to latency of NREM and REM
sleep during a 24-h recording.
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Chapter 4: Discussion
Opioids are effective for pain management. However, all opioids cause many unwanted
side effects including respiratory depression,39,40 delayed wound healing,30 and disruption of
sleep.1,2,6 The purpose of this study was to determine the effects of systemically administered
morphine, fentanyl, and buprenorphine on states of sleep and wakefulness in B6 mice. The main
finding of this study is that all measures of sleep in B6 mice were disrupted by acute opioid
administration. Furthermore, the largest disruption in sleep was caused by buprenorphine, which
is FDA approved for treatment for OUD.12 Previous literature has indicated that sleep disruption
is the number one predictor of relapse for substance abuse disorders.28,29 Poor sleep quality has
been shown to increase drug cravings,41 exacerbate negative emotional states (associated with
relapse),32 and increase depressive symptoms.27 Sleep disruption can also cause hyperalgesia
(increased perception of pain), which leads to higher doses of opioids required for
antinociception.13,33 Differential effects of the three opioids on sleep are most likely due to
pharmacokinetic and pharmacodynamic differences among these drugs, especially the half-life
and potency.
Based on measures of 24-h sleep architecture and time-course of behavioral states
following opioid administration reported in this study, buprenorphine caused longer sleep
disruption compared to fentanyl or morphine before normalizing, relative to saline. This is likely
related to the longer half-life of buprenorphine in comparison with morphine or fentanyl.25
Results in this study also indicate that morphine caused a larger disruption in sleep and
wakefulness (relative to saline) than fentanyl, especially during a 24-h recording. Morphine and
fentanyl are both full mu-opioid receptor agonists; however, fentanyl is 50 to 100-times more
potent, has a higher intrinsic efficacy at mu-opioid receptors, and a shorter half-life.26 Morphine
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causes a large increase in cortical histamine42 and monoamines (such as histamine) have long
been implicated in actively promoting wakefulness.13
Opioid-induced changes illustrated in this study created significantly different behavioral
states based on physiological measures than normal states of sleep and wakefulness.13,18 Mice in
this study exhibited increased ambulation accompanied by the Straub effect43 (a long-standing
bioassay for morphine characterized by the tail pointed straight up in the air) following opioid
administration. This finding is consistent with previous literature, which indicates that morphine
and buprenorphine administered systemically to mice causes an increase in motor activity and in
rats causes a loss of descending inhibition that is seen in the tail.44 Disruptions in the sleep/wake
cycle were illustrated qualitatively by EEG/EMG signals (Fig. 3) and graphs of 4-h sleep
architecture following saline or opioid administration (Fig. 4). Further quantitative analysis
elucidated disruption of major elements of healthy sleep architecture including: percent of time
spent in states of sleep and wakefulness (Fig. 5 & 6), time course and light/dark phases of sleep
(Fig. 7 & 8), number of episodes for each behavioral state (Fig. 9 & 10), duration of the episodes
(Fig. 11 & 12), and the latency to onset of sleep (Fig. 13 & 14). These results collectively
indicate that systemic opioid administration disrupts sleep/wake states in B6 mice.

Percent time in behavioral states was disrupted by opioids
Opioids caused an increase in the percent of time mice spent awake and decreased the
percent of time spent in both NREM and REM sleep (Fig. 5 & 6). Morphine eliminated NREM
sleep and buprenorphine eliminated both NREM and REM sleep in a 4-h recording (Fig. 5). The
measure of sleep and wakefulness during control conditions of the present study were evaluated
relative to previously published data describing the percent of time (mean ± SD) B6 mice
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typically spend in states of wakefulness (59.4 ± 1.8), NREM sleep (35.6 ± 1.5) and REM sleep
(4.8 ± 0.3) during a 24-h period.45 Values reported in this study for 24-h sleep recordings
following saline administration were within ± one standard deviation to those reported in
previous literature. After injections of saline (control), NREM and REM sleep values were
higher during the light cycle than during the dark cycle. This is in line with the physiology of
these nocturnal animals. However even during the light phase, a time interval when these
animals are typically sleeping, NREM and REM sleep were significantly decreased or eliminated
by systemic opioid administration. Results from this study are consistent with data showing that
patients receiving opioid treatments experience increased time awake and less overall sleep.3,4
The present results from B6 mice are consistent with reports that morphine decreases NREM
sleep in cats,11 and decreases NREM and REM sleep in rats9,10 and healthy humans.13
Systemically administered buprenorphine increases time spent in wakefulness and decreases both
NREM and REM sleep in rats.8 Such findings suggest opioid-induced disruption of restorative
sleep13 and memory consolidation.46 Altogether, the decrease in sleep following acute
administration of fentanyl, morphine, or buprenorphine in this study is consistent with the
hypothesis that systemically administered opioids disrupts sleep/wake states in B6 mice.

Opioids altered time course and light/dark cycle
The present study found that systemically administered fentanyl, morphine, and
buprenorphine altered the time course (Fig. 7) of behavioral states during the light and dark
periods (Fig. 8). After administration of fentanyl and morphine, sleep/wake states did not return
to control levels for 4 h and 6 h, respectively. Fentanyl and buprenorphine caused sleep
disruption lasting 4 h and 10 h post-injection with an increase in REM sleep at 14 h and 16 h,
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respectively, during the dark cycle (Fig. 7). These data indicated that opioid administration
caused significantly more time in wakefulness and less time in NREM and REM sleep during the
light cycle when compared to saline. The REM sleep inhibition caused by fentanyl and
buprenorphine was followed by a rebound increase in REM sleep during the dark cycle (Fig. 8).
These results are of interest relative to previous studies indicating opioid use in humans is
associated with increased daytime sleepiness,5 poor daytime function,1 and reduced nighttime
sleep quality.3,4

Number of episodes was decreased by opioids
Opioids decreased the number of waking, NREM, and REM sleep episodes when
compared to saline (Fig. 9 & 10). Following fentanyl, morphine, or buprenorphine
administration, REM sleep episodes displayed a rebound increase during the dark cycle of the
24-h period (Fig. 10). This is likely due to decreased REM sleep episodes during the light cycle
following opioid injection. Previous studies indicate opioid use causes abnormal sleep patterns5,6
and disrupts multiple metrics of healthy sleep function.3,13 The number of sleep/wake episodes is
directly relevant as a functional metric of sleep health as a biological rhythm.13,14,47

The duration of individual sleep/wake episodes were disrupted by opioids
Opioids increased the duration of waking episodes and decreased the duration of both
NREM and REM sleep episodes in a 4-h recording (Fig. 11). Recordings that were maintained
for 24 h post-injection revealed that opioids disrupted the duration of both NREM and REM
sleep episodes and illustrated that the trend is for opioids to increase the duration of waking
episodes (Fig. 12). To facilitate the most conservative statistical analysis, data from all mice
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were included in the Two-way ANOVA for the duration of waking episodes. Differences in
sample sizes between treatment conditions dramatically increases the type-1 error rate for
ANOVA by violating the assumption of equal variances.48 The number of episodes for each
measured behavioral state decreased during a 4-h recording, which resulted in more time spent in
each state. This can also be understood as a hydraulic model (i.e., as one measure decreases, the
other increases and vice versa) with the number of episodes. These findings are consistent with
previous literature indicating opioid usage in humans is associated with longer periods of
wakefulness and shorter sleep intervals.7 Such effects in humans are important because the
duration of sleep episodes (similar to number of episodes) is one measure of restful sleep.13,14,47

Opioids increased latency to onset of sleep
This study found that opioids increased the latency to onset of sleep (Fig. 13 & 14). Mice
required significantly more time to enter states of NREM and REM sleep after opioid injection
compared to saline. The differences in sample sizes between saline and opioid conditions for 4-h
recordings based on elimination of NREM and REM sleep following opioid injection limited the
ability to perform ANOVA.48 This heterogeneity of variance required that non-parametric tests
be used for this analysis. The Wilcoxon signed rank (non-parametric) test was utilized for
analysis of 4-h recordings, because it compared an equal number of samples between saline and
opioid treatment conditions in this model (i.e., 4 h recordings following injection saline versus
fentanyl or morphine recordings, which contained NREM or REM sleep) and was unencumbered
by the differences in sample size.49 Buprenorphine administered systemically causes increased
sleep latency in rats8 and opioid use in humans is associated with increased sleep latency.3,7
Delayed sleep latency is commonly associated with poor sleep quality and sleep disorders such
as insomnia and narcolepsy.50
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Limitations & Future Directions
Limitations of this study include use of only adult male mice, and it is well understood
that there are gender and age differences in sleep quality and in sleep disorders.51,52 This study
chose to model clinical application of opioids by way of systemic drug delivery. The present
results encourage future studies that use chronic administration of opioids. Sleep disturbance can
increase over time during methadone treatment for OUD7 and chronic opioid administration is
common for management of cancer pain. The present study was also limited to studying the B6
line of mice. Another advantage of using mice is the availability of transgenic lines to model
various diseases. The present results encourage the use of obese mice that lack leptin or have
disrupted leptin receptors. In addition to functioning as a satiety factor, leptin status alters the
antinociceptive effects of opioids.53 Finally, the present results also encourage future studies that
aim to evaluate dose-response relationships for the effects of fentanyl, morphine, and
buprenorphine on NREM and REM sleep.
Despite the foregoing limitations, the present findings provide novel evidence that
opioids cause sleep disruption in B6 mice that are similar to the sleep disruption caused by
opioids in humans. These similar opioid effects are consistent with the close homology between
the human and B6 mouse genome. Considered together, the results support the likelihood that
studies of opioid effects using the B6 mouse will help provide a better understanding of the
mechanisms underlying opioid-induced sleep disruption in humans.
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